Hormonal
GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide) produce significant weight loss (6–30%+ TBWL) and improve fertility outcomes (spontaneous conception, IVF pregnancy rates) in women with obesity and PCOS when used in the preconception period.
If you have obesity and are trying to conceive, GLP-1 medications (like Wegovy or Zepbound) are highly effective for weight loss and improving fertility, especially if you have PCOS. You must stop taking them 2 months before you try to conceive to ensure the drug is out of your system. Work with your doctor to manage side effects and costs.
GLP1-RAs reduce food cravings, appetite, and “food noise” and improve insulin sensitivity and satiety, all of which lead to significant weight loss, ranging from 6 to 30% of starting total body weight or greater... GLP-1 RAs can reverse polycystic ovary morphology and decrease serum concentrations of androgens... Elkind-Hirsch et al. illustrated enhanced menstrual regularity and improved rates of conception in women suffering from overweight or obesity with PCOS treated with GLP-1 RAs in the preconception period
Why this rating
Based on a narrative review citing multiple RCTs (STEP, SURMOUNT, COMBI) and observational studies.
Source
Medical therapy to treat obesity and optimize fertility in women of reproductive age: a narrative review
Janelle Duah et al. · Reproductive Biology and Endocrinology · 2025
DOI 10.1186/s12958-024-01339-y
More from this paper
- Bariatric surgery is not first-line therapy for women of reproductive age hoping to conceive quickly due to risks of nutrient deficiencies and the required 1-2 year delay before pregnancy.Strong
- Contrave (naltrexone/bupropion) promotes weight loss (~6% TBWL) and may improve fertility by mitigating PCOS and endometriosis effects, though it is less effective than GLP-1 RAs.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →